No Data
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data
Express News | Edgewise Therapeutics Shares Down 2.7% in Volume Spike
Express News | Edgewise Therapeutics: Warning Letter by FDA to DR. Han Phan Is Unrelated to Any Edgewise Clinical Trial or Data
Express News | Edgewise Therapeutics- Believes Data Related to Co's Clinical Trials at Phan's Site Are Acquired & Stored in Accordance With FDA Requirements
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long